{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:21:25Z","timestamp":1793715685665,"version":"4.6.1"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Pancreatic cancer stands among the most aggressive and fatal malignancies, with a steadily increasing incidence worldwide. Its clinical significance lies not only in its high mortality rate but also in the challenges associated with its early detection, limited therapeutic efficacy, and substantial impact on healthcare systems. The asymptomatic nature of the disease in its initial stages, combined with the absence of reliable early biomarkers, contributes to frequent late-stage diagnoses, significantly compromising treatment success and patient survival. Furthermore, the biological complexity of pancreatic tumors \u2013 often marked by specific genetic mutations and a highly immunosuppressive tumor microenvironment \u2013 drives resistance to conventional therapies, exacerbating clinical management difficulties.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Main body<\/jats:title>\n            <jats:p>This narrative review offers a comprehensive synthesis of the major therapeutic challenges and recent advances in pancreatic cancer management over the past fifteen years. The main challenges include delayed diagnosis, the presence of treatment-resistant tumor subtypes, and the considerable financial burden of care. Particular attention is given to the tumor microenvironment, which impedes drug delivery and immune system activation due to its dense fibrotic stroma and immunosuppressive cellular composition. The review also explores emerging therapeutic strategies, including combination chemotherapy regimens such as folinic acid, fluorouracil, irinotecan, and oxaliplatin, and advanced radiotherapy techniques that aim to enhance precision while minimizing tissue damage. Furthermore, novel immunotherapeutic approaches \u2013 including messenger RNA-based vaccines and engineered cellular therapies \u2013 show promising results in stimulating targeted immune responses, although they face substantial barriers due to the tumor\u2019s immune evasion mechanisms. Targeted therapies focused on specific genetic alterations, especially those involving KRAS mutations, are also highlighted as potential breakthroughs. The review concludes by emphasizing the relevance of personalized medicine, with biomarker-driven strategies and three-dimensional tumor models offering more tailored and potentially effective interventions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Despite meaningful progress in the development of innovative therapeutic modalities, pancreatic cancer continues to present profound medical and scientific challenges. Integrating personalized, interdisciplinary approaches and advancing early diagnostic tools remain essential steps toward improving clinical outcomes and extending survival in affected patients. This review underscores the urgent need for continued research to transform current insights into effective and accessible treatment strategies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s43046-025-00323-w","type":"journal-article","created":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T23:02:57Z","timestamp":1759705377000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pancreatic cancer in the era of precision medicine: challenges, advances, and the future of therapeutic strategies"],"prefix":"10.1186","volume":"37","author":[{"given":"Heslley Machado","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reginaldo Cruz Alves","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"323_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"323_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14740\/wjon1166","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol. 2019;10:10.","journal-title":"World J Oncol"},{"key":"323_CR3","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ijc.34740","volume":"154","author":"Z Yu","year":"2024","unstructured":"Yu Z, et al. Differences in the incidence and mortality of digestive cancer between Global Cancer Observatory 2020 and Global Burden of Disease 2019. Int J Cancer. 2024;154:615\u201325.","journal-title":"Int J Cancer"},{"key":"323_CR4","unstructured":"McGuigan C, Reynolds R, Wiedmer D. Poverty and climate change: assessing impacts in developing countries and the initiatives of the international community. London Sch Econ Consult. Proj Overseas Dev Inst. 2002;1\u201340.\u00a0https:\/\/odi.org\/documents\/2557\/3449.pdf."},{"key":"323_CR5","doi-asserted-by":"publisher","first-page":"9694","DOI":"10.3748\/wjg.v22.i44.9694","volume":"22","author":"M Ilic","year":"2016","unstructured":"Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22:9694.","journal-title":"World J Gastroenterol"},{"key":"323_CR6","doi-asserted-by":"publisher","first-page":"438","DOI":"10.21147\/j.issn.1000-9604.2023.05.03","volume":"35","author":"W Luo","year":"2023","unstructured":"Luo W, et al. Epidemiology of pancreatic cancer: New version, new vision. Chin J Cancer Res. 2023;35:438.","journal-title":"Chin J Cancer Res"},{"key":"323_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nrclinonc.2015.53","volume":"12","author":"I Garrido-Laguna","year":"2015","unstructured":"Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 2015;12:319\u201334.","journal-title":"Nat Rev Clin Oncol"},{"key":"323_CR8","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"323_CR9","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook CJ, Lyssiotis CA, di Magliano MP, Maitra A. Pancreatic cancer: advances and challenges. Cell. 2023;186:1729\u201354.","journal-title":"Cell"},{"key":"323_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23:27\u201347.","journal-title":"Cell Metab"},{"key":"323_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.pan.2014.10.001","volume":"15","author":"M Hidalgo","year":"2015","unstructured":"Hidalgo M, et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology. 2015;15:8\u201318.","journal-title":"Pancreatology"},{"key":"323_CR12","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1056\/NEJMra1404198","volume":"371","author":"DP Ryan","year":"2014","unstructured":"Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371:1039\u201349.","journal-title":"N Engl J Med"},{"key":"323_CR13","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.3390\/cancers15061911","volume":"15","author":"E Cipora","year":"2023","unstructured":"Cipora E, et al. Treatment costs and social burden of pancreatic cancer. Cancers (Basel). 2023;15:1911.","journal-title":"Cancers (Basel)"},{"key":"323_CR14","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1634\/theoncologist.2017-0481","volume":"23","author":"DR Kaye","year":"2018","unstructured":"Kaye DR, et al. Costs of cancer care across the disease continuum. Oncologist. 2018;23:798\u2013805.","journal-title":"Oncologist"},{"key":"323_CR15","doi-asserted-by":"publisher","unstructured":"Khan MA. et al. Morbidity and mortality following surgery for pancreatic cancer in low\u2010and middle\u2010income countries: a systematic review and meta\u2010analysis. J Surg Oncol. 2024.\u00a0https:\/\/doi.org\/10.1002\/jso.27946.","DOI":"10.1002\/jso.27946"},{"key":"323_CR16","doi-asserted-by":"publisher","first-page":"e439","DOI":"10.1200\/OP.22.00536","volume":"19","author":"S Arjani","year":"2023","unstructured":"Arjani S, et al. Neoadjuvant treatment versus upfront surgery in resectable pancreatic cancer: a cost-effectiveness analysis. JCO Oncol Pract. 2023;19:e439\u201348.","journal-title":"JCO Oncol Pract"},{"key":"323_CR17","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","volume":"24","author":"A McGuigan","year":"2018","unstructured":"McGuigan A, et al. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24:4846.","journal-title":"World J Gastroenterol"},{"key":"323_CR18","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1053\/j.gastro.2019.01.259","volume":"156","author":"AD Singhi","year":"2019","unstructured":"Singhi AD, Koay EJ, Chari ST, Maitra A. Early detection of pancreatic cancer: opportunities and challenges. Gastroenterology. 2019;156:2024\u201340.","journal-title":"Gastroenterology"},{"key":"323_CR19","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1097\/MPA.0000000000000701","volume":"45","author":"BJ Kenner","year":"2016","unstructured":"Kenner BJ, et al. Early detection of pancreatic cancer\u2014a defined future using lessons from other cancers: a white paper. Pancreas. 2016;45:1073\u20139.","journal-title":"Pancreas"},{"key":"323_CR20","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.3390\/jcm13164706","volume":"13","author":"Y Shah","year":"2024","unstructured":"Shah Y, et al. Advancements in early detection and screening strategies for pancreatic cancer: from genetic susceptibility to novel biomarkers. J Clin Med. 2024;13:4706.","journal-title":"J Clin Med"},{"key":"323_CR21","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913\u201321.","journal-title":"Cancer Res"},{"key":"323_CR22","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1186\/s12889-024-17875-6","volume":"24","author":"R He","year":"2024","unstructured":"He R, Jiang W, Wang C, Li X, Zhou W. Global burden of pancreatic cancer attributable to metabolic risks from 1990 to 2019, with projections of mortality to 2030. BMC Public Health. 2024;24:456.","journal-title":"BMC Public Health"},{"key":"323_CR23","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1586\/14737140.2016.1168698","volume":"16","author":"S Myrehaug","year":"2016","unstructured":"Myrehaug S, et al. Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions. Expert Rev Anticancer Ther. 2016;16:523\u201330.","journal-title":"Expert Rev Anticancer Ther"},{"key":"323_CR24","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ijrobp.2009.08.046","volume":"78","author":"A Mahadevan","year":"2010","unstructured":"Mahadevan A, et al. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2010;78:735\u201342.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"323_CR25","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1017\/erm.2021.26","volume":"23","author":"D Cao","year":"2021","unstructured":"Cao D, et al. Opportunities and challenges in targeted therapy and immunotherapy for pancreatic cancer. Expert Rev Mol Med. 2021;23:e21.","journal-title":"Expert Rev Mol Med"},{"key":"323_CR26","doi-asserted-by":"publisher","first-page":"1900236","DOI":"10.1002\/adbi.201900236","volume":"5","author":"X Liu","year":"2021","unstructured":"Liu X, Li Z, Wang Y. Advances in targeted therapy and immunotherapy for pancreatic cancer. Adv Biol. 2021;5:1900236.","journal-title":"Adv Biol"},{"key":"323_CR27","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1056\/NEJMp1500523","volume":"372","author":"FS Collins","year":"2015","unstructured":"Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793\u20135.","journal-title":"N Engl J Med"},{"key":"323_CR28","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1001\/jama.2015.3595","volume":"313","author":"EA Ashley","year":"2015","unstructured":"Ashley EA. The precision medicine initiative: a new national effort. JAMA. 2015;313:2119\u201320.","journal-title":"JAMA"},{"key":"323_CR29","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1179\/2047480615Z.000000000329","volume":"24","author":"R Ferrari","year":"2015","unstructured":"Ferrari R. Writing narrative style literature reviews. Med Writ. 2015;24:230\u20135.","journal-title":"Med Writ"},{"key":"323_CR30","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.hlc.2018.03.027","volume":"27","author":"AT Gregory","year":"2018","unstructured":"Gregory AT, Denniss AR. An introduction to writing narrative and systematic reviews\u2014tasks, tips and traps for aspiring authors. Heart Lung Circ. 2018;27:893\u20138.","journal-title":"Heart Lung Circ"},{"key":"323_CR31","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/nrclinonc.2016.109","volume":"13","author":"W Hamilton","year":"2016","unstructured":"Hamilton W, Walter FM, Rubin G, Neal RD. Improving early diagnosis of symptomatic cancer. Nat Rev Clin Oncol. 2016;13:740\u20139.","journal-title":"Nat Rev Clin Oncol"},{"key":"323_CR32","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","volume":"378","author":"A Vincent","year":"2011","unstructured":"Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607\u201320.","journal-title":"Lancet"},{"key":"323_CR33","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1470-2045(08)70337-1","volume":"10","author":"R Pannala","year":"2009","unstructured":"Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009;10:88\u201395.","journal-title":"Lancet Oncol"},{"key":"323_CR34","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/cac2.12204","volume":"41","author":"J Yang","year":"2021","unstructured":"Yang J, et al. Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review. Cancer Commun. 2021;41:1257\u201374.","journal-title":"Cancer Commun"},{"key":"323_CR35","first-page":"1","volume":"3","author":"J Kleeff","year":"2017","unstructured":"Kleeff J, et al. Chronic pancreatitis. Nat Rev Dis Prim. 2017;3:1\u201318.","journal-title":"Nat Rev Dis Prim"},{"key":"323_CR36","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrc.2016.66","volume":"16","author":"A Makohon-Moore","year":"2016","unstructured":"Makohon-Moore A, Iacobuzio-Donahue CA. Pancreatic cancer biology and genetics from an evolutionary perspective. Nat Rev Cancer. 2016;16:553\u201365.","journal-title":"Nat Rev Cancer"},{"key":"323_CR37","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41575-021-00463-z","volume":"18","author":"A Hayashi","year":"2021","unstructured":"Hayashi A, Hong J, Iacobuzio-Donahue CA. The pancreatic cancer genome revisited. Nat Rev Gastroenterol Hepatol. 2021;18:469\u201381.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"323_CR38","doi-asserted-by":"publisher","first-page":"1369136","DOI":"10.3389\/fmed.2024.1369136","volume":"11","author":"A Linehan","year":"2024","unstructured":"Linehan A, O\u2019Reilly M, McDermott R, O\u2019Kane GM. Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies. Front Med. 2024;11:1369136.","journal-title":"Front Med"},{"key":"323_CR39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","volume":"17","author":"L Buscail","year":"2020","unstructured":"Buscail L, Bournet B, Cordelier P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2020;17:153\u201368.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"323_CR40","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021;6:386.","journal-title":"Signal Transduct Target Ther"},{"key":"323_CR41","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-024-01631-9","volume":"17","author":"X Yang","year":"2024","unstructured":"Yang X, Wu H. RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms. J Hematol Oncol. 2024;17:108.","journal-title":"J Hematol Oncol"},{"key":"323_CR42","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","volume":"14","author":"J Dilly","year":"2024","unstructured":"Dilly J, et al. Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer. Cancer Discov. 2024;14:2135\u201361.","journal-title":"Cancer Discov"},{"key":"323_CR43","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell N, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495\u2013501.","journal-title":"Nature"},{"key":"323_CR44","unstructured":"Olive K P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;(80-. ). 324, 1457\u20131461."},{"key":"323_CR45","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","volume":"21","author":"PP Provenzano","year":"2012","unstructured":"Provenzano PP, et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21:418\u201329.","journal-title":"Cancer Cell"},{"key":"323_CR46","doi-asserted-by":"publisher","unstructured":"Herting CJ, Karpovsky I, Lesinski GB. The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions. Cancer Metastasis Rev. 2021:1\u201315.\u00a0https:\/\/doi.org\/10.1007\/s10555-021-09988-w.","DOI":"10.1007\/s10555-021-09988-w"},{"key":"323_CR47","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","volume":"18","author":"MH Sherman","year":"2023","unstructured":"Sherman MH, Beatty GL. Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance. Annu Rev Pathol Mech Dis. 2023;18:123\u201348.","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"323_CR48","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/s41419-022-05351-1","volume":"13","author":"T Zhang","year":"2022","unstructured":"Zhang T, Ren Y, Yang P, Wang J, Zhou H. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Cell Death Dis. 2022;13:897.","journal-title":"Cell Death Dis"},{"key":"323_CR49","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.matbio.2018.11.001","volume":"81","author":"R Malik","year":"2019","unstructured":"Malik R, et al. Rigidity controls human desmoplastic matrix anisotropy to enable pancreatic cancer cell spread via extracellular signal-regulated kinase 2. Matrix Biol. 2019;81:50\u201369.","journal-title":"Matrix Biol"},{"key":"323_CR50","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1200\/JCO.21.02616","volume":"40","author":"NA Ullman","year":"2022","unstructured":"Ullman NA, Burchard PR, Dunne RF, Linehan DC. Immunologic strategies in pancreatic cancer: making cold tumors hot. J Clin Oncol. 2022;40:2789\u2013805.","journal-title":"J Clin Oncol"},{"key":"323_CR51","doi-asserted-by":"publisher","first-page":"605619","DOI":"10.3389\/fimmu.2020.605619","volume":"11","author":"RH Vonderheide","year":"2020","unstructured":"Vonderheide RH, Bear AS. Tumor-derived myeloid cell chemoattractants and T cell exclusion in pancreatic cancer. Front Immunol. 2020;11:605619.","journal-title":"Front Immunol"},{"key":"323_CR52","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s12032-024-02443-0","volume":"41","author":"MJ Saadh","year":"2024","unstructured":"Saadh MJ, et al. Targeting the pancreatic tumor microenvironment by plant-derived products and their nanoformulations. Med Oncol. 2024;41:201.","journal-title":"Med Oncol"},{"key":"323_CR53","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/nature13611","volume":"514","author":"A Viale","year":"2014","unstructured":"Viale A, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014;514:628\u201332.","journal-title":"Nature"},{"key":"323_CR54","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1136\/gutjnl-2015-309304","volume":"64","author":"A Neesse","year":"2015","unstructured":"Neesse A, Alg\u00fcl H, Tuveson DA, Gress TM. Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut. 2015;64:1476\u201384.","journal-title":"Gut"},{"key":"323_CR55","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1142\/S1793048020300042","volume":"15","author":"X Li","year":"2020","unstructured":"Li X, Thirumalai D. Cooperation among tumor cell subpopulations leads to intratumor heterogeneity. Biophys Rev Lett. 2020;15:99\u2013119.","journal-title":"Biophys Rev Lett"},{"key":"323_CR56","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/bs.acr.2023.02.005","volume":"159","author":"AM Palma","year":"2023","unstructured":"Palma AM, Vudatha V, Peixoto ML, Madan E. Tumor heterogeneity: an oncogenic driver of PDAC progression and therapy resistance under stress conditions. Adv Cancer Res. 2023;159:203\u201349.","journal-title":"Adv Cancer Res"},{"key":"323_CR57","doi-asserted-by":"publisher","first-page":"20180820","DOI":"10.1098\/rsif.2018.0820","volume":"16","author":"X Li","year":"2019","unstructured":"Li X, Thirumalai D. Share, but unequally: a plausible mechanism for emergence and maintenance of intratumour heterogeneity. J R Soc Interface. 2019;16:20180820.","journal-title":"J R Soc Interface"},{"key":"323_CR58","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s11605-022-05553-0","volume":"27","author":"EE Montalvo-Jav\u00e9","year":"2023","unstructured":"Montalvo-Jav\u00e9 EE, et al. Pancreatic cancer: genetic conditions and epigenetic alterations. J Gastrointest Surg. 2023;27:1001\u201310.","journal-title":"J Gastrointest Surg"},{"key":"323_CR59","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med"},{"key":"323_CR60","doi-asserted-by":"publisher","unstructured":"Milella M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011:768\u2013769.\u00a0https:\/\/doi.org\/10.1056\/NEJMoa1011923.","DOI":"10.1056\/NEJMoa1011923"},{"key":"323_CR61","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","volume":"17","author":"M Suker","year":"2016","unstructured":"Suker M, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17:801\u201310.","journal-title":"Lancet Oncol"},{"key":"323_CR62","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703.","journal-title":"N Engl J Med"},{"key":"323_CR63","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12957-021-02291-6","volume":"19","author":"B Zhang","year":"2021","unstructured":"Zhang B, et al. The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis. World J Surg Oncol. 2021;19:182.","journal-title":"World J Surg Oncol"},{"key":"323_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-26811-9","volume":"8","author":"H Tong","year":"2018","unstructured":"Tong H, Fan Z, Liu B, Lu T. The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis. Sci Rep. 2018;8:1\u20138.","journal-title":"Sci Rep"},{"key":"323_CR65","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon J, et al. The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575:217\u201323.","journal-title":"Nature"},{"key":"323_CR66","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","volume":"19","author":"AR Moore","year":"2020","unstructured":"Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov. 2020;19:533\u201352.","journal-title":"Nat Rev Drug Discov"},{"key":"323_CR67","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1183\/16000617.0071-2015","volume":"25","author":"E Kempf","year":"2016","unstructured":"Kempf E, Rousseau B, Besse B, Paz-Ares L. KRAS oncogene in lung cancer: focus on molecularly driven clinical trials. Eur Respir Rev. 2016;25:71\u20136.","journal-title":"Eur Respir Rev"},{"key":"323_CR68","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13751","author":"S Miyazaki","year":"2025","unstructured":"Miyazaki S, et al. Targeting KRAS-mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2. Mol Oncol. 2025. https:\/\/doi.org\/10.1002\/1878-0261.13751.","journal-title":"Mol Oncol"},{"key":"323_CR69","doi-asserted-by":"publisher","unstructured":"Contreras CT. et al. KRAS G12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. Mol Oncol.\u00a0https:\/\/doi.org\/10.1002\/1878-0261.13725.","DOI":"10.1002\/1878-0261.13725"},{"key":"323_CR70","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","volume":"388","author":"JH Strickler","year":"2023","unstructured":"Strickler JH, et al. Sotorasib in KRAS p. G12C\u2013mutated advanced pancreatic cancer. N Engl J Med. 2023;388:33\u201343.","journal-title":"N Engl J Med"},{"key":"323_CR71","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong DS, et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383:1207\u201317.","journal-title":"N Engl J Med"},{"key":"323_CR72","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","volume":"10","author":"J Hallin","year":"2020","unstructured":"Hallin J, et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 2020;10:54\u201371.","journal-title":"Cancer Discov"},{"key":"323_CR73","unstructured":"Le DT. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017 (80-. ). 357, 409\u2013413."},{"key":"323_CR74","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509\u201320.","journal-title":"N Engl J Med"},{"key":"323_CR75","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","volume":"5","author":"EM O\u2019Reilly","year":"2019","unstructured":"O\u2019Reilly EM, et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2019;5:1431\u20138.","journal-title":"JAMA Oncol"},{"key":"323_CR76","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618:144\u201350.","journal-title":"Nature"},{"key":"323_CR77","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s00262-024-03632-6","volume":"73","author":"X Ye","year":"2024","unstructured":"Ye X, Yu Y, Zheng X, Ma H. Clinical immunotherapy in pancreatic cancer. Cancer Immunol Immunother. 2024;73:64.","journal-title":"Cancer Immunol Immunother"},{"key":"323_CR78","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12943-020-01151-3","volume":"19","author":"J Fan","year":"2020","unstructured":"Fan J, et al. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma. Mol Cancer. 2020;19:32.","journal-title":"Mol Cancer"},{"key":"323_CR79","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","volume":"386","author":"R Leidner","year":"2022","unstructured":"Leidner R, et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N Engl J Med. 2022;386:2112\u20139.","journal-title":"N Engl J Med"},{"key":"323_CR80","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13045-023-01491-9","volume":"16","author":"C Qi","year":"2023","unstructured":"Qi C, et al. CT041 CAR T cell therapy for Claudin18. 2-positive metastatic pancreatic cancer. J Hematol Oncol. 2023;16:102.","journal-title":"J Hematol Oncol"},{"key":"323_CR81","doi-asserted-by":"publisher","first-page":"1325860","DOI":"10.3389\/fimmu.2024.1325860","volume":"15","author":"G Zhong","year":"2024","unstructured":"Zhong G, et al. Complete remission of advanced pancreatic cancer induced by claudin18. 2-targeted CAR-T cell therapy: a case report. Front Immunol. 2024;15:1325860.","journal-title":"Front Immunol"},{"key":"323_CR82","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.prro.2016.05.005","volume":"6","author":"AD Rao","year":"2016","unstructured":"Rao AD, et al. Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer. Pract Radiat Oncol. 2016;6:417\u201324.","journal-title":"Pract Radiat Oncol"},{"key":"323_CR83","doi-asserted-by":"publisher","first-page":"465","DOI":"10.21873\/anticanres.13975","volume":"40","author":"A Arcelli","year":"2020","unstructured":"Arcelli A, et al. Higher biologically effective dose predicts survival in SBRT of pancreatic cancer: a multicentric analysis (PAULA-1). Anticancer Res. 2020;40:465\u201372.","journal-title":"Anticancer Res"},{"key":"323_CR84","unstructured":"Narayanan, G. Irreversible electroporation for treatment of liver cancer. Gastroenterol Hepatol (N. Y). 2011;7:313."},{"key":"323_CR85","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.3390\/ijms24054381","volume":"24","author":"A Gajewska-Naryniecka","year":"2023","unstructured":"Gajewska-Naryniecka A, et al. Irreversible electroporation in pancreatic cancer\u2014an evolving experimental and clinical method. Int J Mol Sci. 2023;24:4381.","journal-title":"Int J Mol Sci"},{"key":"323_CR86","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.ejso.2014.08.480","volume":"40","author":"J Moir","year":"2014","unstructured":"Moir J, White SA, French JJ, Littler P, Manas DM. Systematic review of irreversible electroporation in the treatment of advanced pancreatic cancer. Eur J Surg Oncol. 2014;40:1598\u2013604.","journal-title":"Eur J Surg Oncol"},{"key":"323_CR87","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/COC.0b013e3181d270b4","volume":"34","author":"J-CM Rwigema","year":"2011","unstructured":"Rwigema J-CM, et al. Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas. Am J Clin Oncol. 2011;34:63\u20139.","journal-title":"Am J Clin Oncol"},{"key":"323_CR88","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.jvir.2010.12.014","volume":"22","author":"KR Thomson","year":"2011","unstructured":"Thomson KR, et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol. 2011;22:611\u201321.","journal-title":"J Vasc Interv Radiol"},{"key":"323_CR89","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.3390\/cancers11111718","volume":"11","author":"S Lafranceschina","year":"2019","unstructured":"Lafranceschina S, et al. Systematic review of irreversible electroporation role in management of locally advanced pancreatic cancer. Cancers (Basel). 2019;11:1718.","journal-title":"Cancers (Basel)"},{"key":"323_CR90","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1101\/gad.1415606","volume":"20","author":"AF Hezel","year":"2006","unstructured":"Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, DePinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006;20:1218\u201349.","journal-title":"Genes Dev"},{"key":"323_CR91","first-page":"2969","volume":"6","author":"RH Hruban","year":"2000","unstructured":"Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res. 2000;6:2969\u201372.","journal-title":"Clin Cancer Res"},{"key":"323_CR92","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317\u201327.","journal-title":"N Engl J Med"},{"key":"323_CR93","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1586\/14737140.2015.1086271","volume":"15","author":"G Luo","year":"2015","unstructured":"Luo G, et al. Pancreatic cancer: BRCA mutation and personalized treatment. Expert Rev Anticancer Ther. 2015;15:1223\u201331.","journal-title":"Expert Rev Anticancer Ther"},{"key":"323_CR94","doi-asserted-by":"publisher","unstructured":"Raphael KL, Willingham FF. Hereditary pancreatitis: current perspectives. Clin Exp Gastroenterol. 2016:197\u2013207.\u00a0https:\/\/doi.org\/10.2147\/CEG.S84358.","DOI":"10.2147\/CEG.S84358"},{"key":"323_CR95","doi-asserted-by":"publisher","first-page":"916","DOI":"10.12659\/MSM.889636","volume":"19","author":"Y Fang","year":"2013","unstructured":"Fang Y, et al. Genetic and molecular alterations in pancreatic cancer: implications for personalized medicine. Med Sci Monit. 2013;19:916.","journal-title":"Med Sci Monit"},{"key":"323_CR96","doi-asserted-by":"publisher","first-page":"2401138","DOI":"10.1002\/adhm.202401138","volume":"13","author":"AC Siciliano","year":"2024","unstructured":"Siciliano AC, et al. A 3D pancreatic cancer model with integrated optical sensors for noninvasive metabolism monitoring and drug screening. Adv Healthc Mater. 2024;13:2401138.","journal-title":"Adv Healthc Mater"},{"key":"323_CR97","doi-asserted-by":"publisher","first-page":"20201397","DOI":"10.1259\/bjr.20201397","volume":"94","author":"G Wishart","year":"2021","unstructured":"Wishart G, Gupta P, Schettino G, Nisbet A, Velliou E. 3D tissue models as tools for radiotherapy screening for pancreatic cancer. Br J Radiol. 2021;94:20201397.","journal-title":"Br J Radiol"},{"key":"323_CR98","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.7150\/thno.42441","volume":"10","author":"E Tom\u00e1s-Bort","year":"2020","unstructured":"Tom\u00e1s-Bort E, Kieler M, Sharma S, Candido JB, Loessner D. 3D approaches to model the tumor microenvironment of pancreatic cancer. Theranostics. 2020;10:5074.","journal-title":"Theranostics"},{"key":"323_CR99","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1126\/science.aar3247","volume":"359","author":"JD Cohen","year":"2018","unstructured":"Cohen JD, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359:926\u201330.","journal-title":"Science"},{"key":"323_CR100","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12943-018-0927-5","volume":"18","author":"D Thomas","year":"2019","unstructured":"Thomas D, Radhakrishnan P. Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. Mol Cancer. 2019;18:14.","journal-title":"Mol Cancer"},{"key":"323_CR101","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/cancers10010006","volume":"10","author":"N Martinez-Bosch","year":"2018","unstructured":"Martinez-Bosch N, Vinaixa J, Navarro P. Immune evasion in pancreatic cancer: from mechanisms to therapy. Cancers (Basel). 2018;10:6.","journal-title":"Cancers (Basel)"},{"key":"323_CR102","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41586-023-06685-2","volume":"623","author":"N Caronni","year":"2023","unstructured":"Caronni N, et al. IL-1\u03b2+ macrophages fuel pathogenic inflammation in pancreatic cancer. Nature. 2023;623:415\u201322.","journal-title":"Nature"},{"key":"323_CR103","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s13046-024-03178-6","volume":"43","author":"H Luo","year":"2024","unstructured":"Luo H, et al. Tumor-associated neutrophils upregulate Nectin2 expression, creating the immunosuppressive microenvironment in pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res. 2024;43:258.","journal-title":"J Exp Clin Cancer Res"},{"key":"323_CR104","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey P, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47\u201352.","journal-title":"Nature"},{"key":"323_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.53964\/cme.2025001","volume":"2","author":"HM Silva","year":"2025","unstructured":"Silva HM. mRNA technology in modern medicine: review and future prospects. Clin Mol Epidemiol. 2025;2:1\u201318.","journal-title":"Clin Mol Epidemiol"},{"key":"323_CR106","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3389\/fimmu.2016.00407","volume":"7","author":"C Saut\u00e8s-Fridman","year":"2016","unstructured":"Saut\u00e8s-Fridman C, et al. Tertiary lymphoid structures in cancers: prognostic value, regulation, and manipulation for therapeutic intervention. Front Immunol. 2016;7:407.","journal-title":"Front Immunol"},{"key":"323_CR107","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","volume":"171","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171:1259\u201371.","journal-title":"Cell"},{"key":"323_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-024-01193-6","volume":"14","author":"Z Tao","year":"2024","unstructured":"Tao Z, et al. Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies. Blood Cancer J. 2024;14:1\u201310.","journal-title":"Blood Cancer J"},{"key":"323_CR109","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","volume":"20","author":"AJ Hou","year":"2021","unstructured":"Hou AJ, Chen LC, Chen YY. Navigating CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug Discov. 2021;20:531\u201350.","journal-title":"Nat Rev Drug Discov"},{"key":"323_CR110","doi-asserted-by":"publisher","first-page":"1140541","DOI":"10.3389\/fimmu.2023.1140541","volume":"14","author":"AX Wang","year":"2023","unstructured":"Wang AX, Ong XJ, D\u2019Souza C, Neeson PJ, Zhu JJ. Combining chemotherapy with CAR-T cell therapy in treating solid tumors. Front Immunol. 2023;14:1140541.","journal-title":"Front Immunol"},{"key":"323_CR111","doi-asserted-by":"publisher","first-page":"813832","DOI":"10.3389\/fimmu.2021.813832","volume":"12","author":"VM Qin","year":"2022","unstructured":"Qin VM, Haynes NM, D\u2019Souza C, Neeson PJ, Zhu JJ. CAR-T plus radiotherapy: a promising combination for immunosuppressive tumors. Front Immunol. 2022;12:813832.","journal-title":"Front Immunol"},{"key":"323_CR112","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser R, Cherkassky L, Chintala N, Adusumilli PS. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell. 2019;36:471\u201382.","journal-title":"Cancer Cell"},{"key":"323_CR113","doi-asserted-by":"crossref","unstructured":"Yamaguchi Y. et al. PD-L1 blockade restores CAR T cell activity through IFN-\u03b3-regulation of CD163+ M2 macrophages. J Immunother Cancer. 2022;10.","DOI":"10.1136\/jitc-2021-004400"},{"key":"323_CR114","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41392-024-01824-1","volume":"9","author":"R Fu","year":"2024","unstructured":"Fu R, et al. Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects. Signal Transduct Target Ther. 2024;9:118.","journal-title":"Signal Transduct Target Ther"},{"key":"323_CR115","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/CCO.0b013e328352ea20","volume":"24","author":"J Gaertner","year":"2012","unstructured":"Gaertner J, Wolf J, Voltz R. Early palliative care for patients with metastatic cancer. Curr Opin Oncol. 2012;24:357\u201362.","journal-title":"Curr Opin Oncol"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00323-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-025-00323-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00323-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T23:03:01Z","timestamp":1759705381000},"score":1,"resource":{"primary":{"URL":"https:\/\/jenci.springeropen.com\/articles\/10.1186\/s43046-025-00323-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":115,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["323"],"URL":"https:\/\/doi.org\/10.1186\/s43046-025-00323-w","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}